NCT00090116

Data

{
  "briefSummary": "Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist).",
  "completionDate": "2005-03",
  "conditions": [
    "Alzheimer's Disease"
  ],
  "enrollmentCount": 400,
  "enrollmentType": null,
  "nctId": "NCT00090116",
  "phase": "PHASE3",
  "sponsorId": "forest-laboratories",
  "startDate": "2003-03",
  "status": "COMPLETED",
  "studyType": "INTERVENTIONAL",
  "title": "A Randomized, Double-Blind,Placebo-Controlled Evaluation of the Safety and Efficacy of Neramexane Monotherapy in Patients With Moderate to Severe Dementia of the Alzheimer's Type",
  "url": "https://clinicaltrials.gov/study/NCT00090116"
}

History in this collection

1. addedv1.0.0Jun 12, 2026this version